Logo.png
Beta Thalassemia Clinical Trials Pipeline Analysis: 22+ Companies are Working to Improve the Treatment Space | DelveInsight
January 09, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Beta Thalassemia Clinical Trials Pipeline Analysis: 22+ Companies are Working to Improve the Treatment Space | DelveInsight The prevalence of...
Inserting Hb Variant cartridge
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET | Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
Imara-Logo-Color-RGB.jpg
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 05, 2022 06:45 ET | Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara-Logo-Color-RGB.jpg
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET | Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara-Logo-Color-RGB.jpg
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 05, 2022 07:00 ET | Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara-Logo-Color-RGB.jpg
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET | Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET | Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara-Logo-Color-RGB.jpg
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
November 16, 2021 07:00 ET | Imara, Inc.
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...
Imara-Logo-Color-RGB.jpg
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
November 09, 2021 07:00 ET | Imara, Inc.
   Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
November 04, 2021 16:01 ET | Imara, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...